Framework contracts for innovative infectious disease therapeutics
Originaltitel der Bekanntmachung
Belgium – Research and development services and related consultancy services – Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases
Opportunity Score
Warum diese Bewertung?
Chance
75 / 100
Komplexität
85 / 100
Risikofaktoren
Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...
Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Strong opportunityWichtige Fakten
- EUR 252M estimated value
- Framework procurement
- Services contract
- 2 lots
- Lot 1: Development of pathogen-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
- Lot 2: Development of host-targeted scalable therapeutics, innovative combination therapies, and alternative IV route products for viral infections, ARDS, or sepsis.
Vollständige Zusammenfassung anzeigen
This Pre-Commercial Procurement (PCP) call, led by the Health and Digital Executive Agency (HaDEA), aims to accelerate the development of innovative medical countermeasures for infectious diseases, specifically next-generation therapeutics. The tender consists of two lots: 'Highly Innovative Therapeutics' (Lot 1, value €138M) focusing on pathogen-targeted scalable therapeutics, and 'Advanced Therapeutics' (Lot 2, value €114M) focusing on host-targeted scalable therapeutics. Both lots include combination therapies and alternative IV routes. The overall estimated value is €252M, funded under EU4Health. The procedure is a negotiated procedure with call for competition, resulting in multiple sourcing framework contracts. Evaluation is 80% quality and 20% price. Submission deadline: 2026-09-02.
Risiken
Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...
Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.
Submission deadline in 8 days
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Must address viral infections, ARDS, or sepsis resulting from infections.
- Pathogen-targeted therapeutics (Lot 1) or host-targeted therapeutics (Lot 2).
- Excludes small molecules, monoclonal antibodies; includes direct/indirect antivirals, immune modulators.
Zuschlagskriterien
Lot 1
Lot 2
Auftraggeber
Ort
Brussels, BEL
Website
Kennung
HADEA
Tätigkeit
General public services
Lose (2)
LOT-0001
Highly Innovative Therapeutics
Lot 1 targets pathogen-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.
EUR 252M
Geschätzter Wert
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Please consult the procurement documents.
Zusätzliche CPV-Codes
Hinweis zum Wert
Originale TED-Daten anzeigen
Originale TED-Beschreibung
Lot 1 targets pathogen targeted scalable therapeutics, innovative combination therapies and therapeutics designed to be administered through alternative routes to IV
LOT-0002
Advanced Therapeutics
Lot 2 targets host-targeted scalable therapeutics, innovative combination therapies, and therapeutics designed for alternative routes to IV administration.
EUR 252M
Geschätzter Wert
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Please consult the procurement documents.
Zusätzliche CPV-Codes
Hinweis zum Wert
Originale TED-Daten anzeigen
Originale TED-Beschreibung
Lot 2 targets host targeted scalable therapeutics, innovative combination therapies and therapeutics designed to be administered through alternative routes to IV
Vergabedetails
- Veröffentlichungsdatum
- 01 Jul 2026
- Sprachen
- English, Bulgarian
Referenzmetadaten
- Rechtsgrundlage
- 32024R2509
Referenz-IDs
- Ausschreibungs-ID
- 456593-2026
Dokumente (2)
Ähnliche Ausschreibungen
Spain – Research and experimental development services – Pre-commercial Procurement of an innovative Systemic Sustainability Transition Solution for Health Care Organisations (suHCO)
France – Research and experimental development services – Chambre d’essais pour des tests en Compatibilité Electro-Magnétique (CEM) d’équipements fonctionnant à l’hydrogène
Belgium – Research and experimental development services – Long-term API stockpiling and rapid finished dose form manufacture
Norway – Research and development services and related consultancy services – Preventive conversations as a means of the police ́s preventive work.
Germany – Research and experimental development services – Toolkit für aktives Verteilnetzmanagement
Norway – Research and development services and related consultancy services – Evaluation of the police's national efforts against criminal networks.
Opportunity Score
Warum diese Bewertung?
Chance
75 / 100
Komplexität
85 / 100
Risikofaktoren
Highly innovative and specialized therapeutic areas (e.g., host-targeted, broad-spectrum) may require cutting-edge R&D...
Procurement documents are not analyzed; detailed requirements, terms, and conditions may impose unforeseen obligations.
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications